<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F5ED0F87-6900-4827-A1E1-608A7AF9C6D7"><gtr:id>F5ED0F87-6900-4827-A1E1-608A7AF9C6D7</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>I</gtr:otherNames><gtr:surname>Polkey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/96CD831F-9F26-449D-B6C8-70C6997A938D"><gtr:id>96CD831F-9F26-449D-B6C8-70C6997A938D</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Hart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/40B8E136-D92C-4B9B-A822-762445BA707C"><gtr:id>40B8E136-D92C-4B9B-A822-762445BA707C</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>Hopkinson</gtr:surname><gtr:orcidId>0000-0003-3235-0454</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9DF7C42-AF11-4540-A4D7-A5CAF1EC1765"><gtr:id>C9DF7C42-AF11-4540-A4D7-A5CAF1EC1765</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Moxham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53656A41-3469-4E16-9429-F0C73E3788DF"><gtr:id>53656A41-3469-4E16-9429-F0C73E3788DF</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:otherNames>Thomas</gtr:otherNames><gtr:surname>Hansel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3A2A74C-3279-4118-8679-4AA45A018811"><gtr:id>E3A2A74C-3279-4118-8679-4AA45A018811</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Kemp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701628"><gtr:id>0BA42E20-7CA8-46AE-A2D6-B82B8B9A2CCE</gtr:id><gtr:title>Impact of ACE inhibition on mechanisms of skeletal muscle wasting in COPD</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701628</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) is a major public health problem in the UK and worldwide. As well as being a lung disease COPD has well-recognised and important consequences for other parts of the body, and these contribute to the enormous burden of disability associated with the condition. Muscle weakness is one of these consequences, and is associated with reduced exercise capacity, reduced quality of life and increased mortality. Since efforts to treat the lung disease have to date had limited impact it is important to address the systemic complications of the disease directly. The molecular pathways involved in muscle wasting are gradually becoming understood. An important signalling pathway in muscle links the hormone insulin-like growth factor with the production of ?atrogenes? which are substances that mark muscle proteins for breakdown. There is evidence in animal models that this could be influenced by drugs called angiotensin converting enzyme inhibitors (ACE-I). This class of drugs are widely used for the treatment of high blood pressure and heart failure, and in fact patients prescribed these drugs for that reason have better preservation of limb muscle than those who receive another class of drug. 
We propose testing this possibility in humans by performing a placebo controlled study of an ACE inhibitor in 70 patients with COPD who have weak quadriceps (one of the main leg muscles). We will measure quadriceps muscle endurance using a repetitive magnetic stimulator before treatment and then after two months on either treatment or placebo. A small sample of muscle will be taken before and after treatment to allow u to study the molecular mechanisms involved.
We hypothesise that ACE inhibitors will cause a reduction in atrogene levels and that this will occur in tandem with an increase in quadriceps strength and endurance. If this is the case it would open the way for a much larger study to see if use of ACE inhibitors could improve exercise capacity and quality of life in people with COPD.</gtr:abstractText><gtr:technicalSummary>Chronic obstructive pulmonary disease (COPD) is projected to become the fifth biggest cause of disability adjusted life years by 2020. Although it is primarily a lung disease it has important systemic complications. Skeletal muscle weakness is one of these but the mechanisms involved in muscle loss are incompletely understood. 
A key catabolic pathway involved in skeletal muscle atrophy is mediated through expression of two muscle-specific ubiquitin ligases, the atrogenes, atrogin-1 and MuRF-1, which are themselves dependent on the activity of FoxO transcription factors. In health these transcription factors are rendered inactive by phosphorylation by AKT. IGF-1 and insulin act through the PI3K/AKT pathway to disable FoxO transcription factors, prevent expression of atrogenes and thus act in an anticatabolic way. There is evidence that there is increased expression of both atrogin-1 and MuRF-1 in skeletal muscle in patients with COPD. Animal studies suggest that angiotensin II may cause muscle wasting via this pathway. 
We therefore wish to test the hypothesis that ACE inhibition will have a beneficial effect on the IGF-1/AKT/FOXO/atrogene pathway of muscle wasting in patients with COPD and that this will be associated with improvements in skeletal muscle function. Skeletal muscle function will be assessed using a novel, non-volitional measure of endurance developed in our laboratory.
We propose a randomised double blind study of ACE inhibition in 70 patients with COPD who have established quadriceps weakness. Patients will have their quadriceps endurance assessed using repetitive magnetic stimulation, a non-volitional technique that we have developed and a muscle biopsy performed to allow us to study the pathways involved. These measures will be repeated after two months and the two groups compared.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>496131</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British lung foundation - open sessions for patients</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>68CC6E46-FB95-487F-8272-E55EB863A75F</gtr:id><gtr:impact>Several occasions when groups of 40-50 patietns attended

Patients expressed interest in participation and interest in research more generally.</gtr:impact><gtr:outcomeId>ReH2ytPYv9q</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spirometry screening</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>E84FD1A0-D2A8-4532-A5B9-A795770A2D55</gtr:id><gtr:impact>Open access spirometry and lung health sessions including discussion of lung research and invitation to register as a potential participant.

Positive impact on smoking cessation and patietn recruitment.</gtr:impact><gtr:outcomeId>sXgTzYMr1bT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>601633</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies - MRC MR/J000620/1</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8B6B3DF2-C218-4D7B-8C40-EDD8DF5605E7</gtr:id><gtr:outcomeId>DR92pJq94DA0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Awarded Grant for &amp;quot;Best Abstracts in Rehabilitation &amp;amp; Chronic Care&amp;quot;</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>European Respiratory Society (ERS)</gtr:fundingOrg><gtr:id>0F37E024-EF2F-425A-9B84-D031B0FF2AC0</gtr:id><gtr:outcomeId>TWKJ5omCzdE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>103000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator Initiated Study Pathway IISP 35790</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>A73C52C5-D323-45EF-AB8C-4FCD63E2D6DF</gtr:id><gtr:outcomeId>p8GhtZ7ZcdZ0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Further trial underway in context of PR</gtr:description><gtr:id>B6B69C00-65F2-432A-B366-2B295B8EC312</gtr:id><gtr:impact>ACE-I were ineffective in this trial but may enahnce the effect of exercise so a new trial is underway to evaluate this.</gtr:impact><gtr:outcomeId>kHxbdmUMuF3</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>ACE trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN05581879</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN05581879/Hopkinson</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A03F2264-71FA-4158-8F89-CB4C61C0FFC6</gtr:id><gtr:title>Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>pm_15341_21_22757959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92FB5681-0205-4C82-B794-027CBC7CF0E6</gtr:id><gtr:title>Chronic obstructive pulmonary disease: consequences beyond the lung.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>pm_15341_21_22372229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20CF0A31-6565-4C89-BBFC-1019B58A002E</gtr:id><gtr:title>Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients.</gtr:title><gtr:parentPublicationTitle>Respiration; international review of thoracic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/666610dadb45314880fe33af34147b87"><gtr:id>666610dadb45314880fe33af34147b87</gtr:id><gtr:otherNames>Kelly JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0025-7931</gtr:issn><gtr:outcomeId>pm_15341_21_22441322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>517F57C6-5C13-4E4D-A8F1-EC947883C84A</gtr:id><gtr:title>Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American Medical Directors Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c328c08c104d291ec03127462ef9c2e5"><gtr:id>c328c08c104d291ec03127462ef9c2e5</gtr:id><gtr:otherNames>Smid DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-8610</gtr:issn><gtr:outcomeId>5a578bb5159994.90137305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F484EB-503F-4595-986B-211B30A3C375</gtr:id><gtr:title>Chronic obstructive pulmonary disease: consequences beyond the lung</gtr:title><gtr:parentPublicationTitle>Clinical Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c1daa5c35e59.81212001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>143E7B5A-636F-4CC2-BE10-ACD5A61B8A6E</gtr:id><gtr:title>Skeletal muscle dysfunction in chronic obstructive pulmonary disease</gtr:title><gtr:parentPublicationTitle>Respiratory Medicine: COPD Update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>5899c4dbe98215.16705882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB7EFC74-02A0-4ABB-ABD3-E3C0E3B6D14D</gtr:id><gtr:title>Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b5fada9cab03f97a497208f78f82732"><gtr:id>7b5fada9cab03f97a497208f78f82732</gtr:id><gtr:otherNames>Mendoza L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>545ceac65a0bb6.19675691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2CC9D1-A5A6-4422-96BF-452E92539AD2</gtr:id><gtr:title>Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a87358746db4a794e3e49a975fcf6ce"><gtr:id>5a87358746db4a794e3e49a975fcf6ce</gtr:id><gtr:otherNames>Spina G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5899c1a221ef76.34100888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B15499F7-A74C-4103-AB85-AE3B10911A98</gtr:id><gtr:title>Patent foramen ovale is not associated with hypoxemia in severe chronic obstructive pulmonary disease and does not impair exercise performance.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a2b6ff1ccfb0a05c266deb23d9b71fa"><gtr:id>8a2b6ff1ccfb0a05c266deb23d9b71fa</gtr:id><gtr:otherNames>Shaikh ZF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>545ceac7dfd835.16391921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5CE92FF-95AE-419E-9855-AFFEF68780FE</gtr:id><gtr:title>Quadriceps wasting and physical inactivity in patients with COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_15341_21_22362854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A98FD48C-2DD7-4BD3-AC00-AB33177AC5C5</gtr:id><gtr:title>A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c678fe8c8421846e745f0ec1ceb9cc28"><gtr:id>c678fe8c8421846e745f0ec1ceb9cc28</gtr:id><gtr:otherNames>Shrikrishna D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>545ceac83c7656.82358651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F7A11FE-9C5B-42EE-9072-5291D6F9107F</gtr:id><gtr:title>Effect of acute exacerbations on skeletal muscle strength and physical activity in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1541de4b05812acff939e6abf996813a"><gtr:id>1541de4b05812acff939e6abf996813a</gtr:id><gtr:otherNames>Wieboldt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1569-1993</gtr:issn><gtr:outcomeId>pm_15341_21_22226413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EA64E98-F23A-4014-81A9-D7516FD9B280</gtr:id><gtr:title>The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2914575cb88c9a6f61c651a7808c58"><gtr:id>8d2914575cb88c9a6f61c651a7808c58</gtr:id><gtr:otherNames>Dodd JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>pm_15341_21_22497561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B076349-8DDA-40F5-8510-E52DEF3BD3C0</gtr:id><gtr:title>Vitamin D and skeletal muscle strength and endurance in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd45906bf540f35a3ca2ee233c637e6"><gtr:id>2fd45906bf540f35a3ca2ee233c637e6</gtr:id><gtr:otherNames>Jackson AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_15341_21_22556020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E569DA28-5755-498C-B1A0-87186F2DE0DC</gtr:id><gtr:title>Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ba2da4f6a48533954ff6ee47894d99a"><gtr:id>9ba2da4f6a48533954ff6ee47894d99a</gtr:id><gtr:otherNames>Waschki B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn><gtr:outcomeId>doi_55f984984908cb35</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B28CE99A-7F65-4D43-8D44-BAD2AD4BBD9F</gtr:id><gtr:title>Bioenergetics and intermuscular fat in chronic obstructive pulmonary disease-associated quadriceps weakness.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cc1f52a2e11082b5e7f742c515428d1"><gtr:id>1cc1f52a2e11082b5e7f742c515428d1</gtr:id><gtr:otherNames>Shields GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>545ceac9497887.78521729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E281671F-2683-4B6D-956E-95A4993CBD25</gtr:id><gtr:title>ACE and response to pulmonary rehabilitation in COPD: two observational studies.</gtr:title><gtr:parentPublicationTitle>BMJ open respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52f1c87ffff0e8195021ade7f080332"><gtr:id>d52f1c87ffff0e8195021ade7f080332</gtr:id><gtr:otherNames>Kon SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2052-4439</gtr:issn><gtr:outcomeId>5a1d85b7b6e369.56529607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B56C7A4-318A-4FF9-8CE1-9C5F027EC470</gtr:id><gtr:title>Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22bedf87b030103b10daf0b1e1966266"><gtr:id>22bedf87b030103b10daf0b1e1966266</gtr:id><gtr:otherNames>Maddocks M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>545ceac9be3258.75706845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E560BC2-919A-4052-8A61-ACED3D6AE53E</gtr:id><gtr:title>Physical activity patterns and clusters in 1001 patients with COPD.</gtr:title><gtr:parentPublicationTitle>Chronic respiratory disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e4a95324c34132f8fc1e93a41761b6"><gtr:id>63e4a95324c34132f8fc1e93a41761b6</gtr:id><gtr:otherNames>Mesquita R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1479-9723</gtr:issn><gtr:outcomeId>5a578c39629b69.24603473</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701628</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>